English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

s / Urological Science 27 (2016) S36eS52 S50 survival (PFS) defined as no biochemical relapse (two consecutive rises in prostate-specific antigen [PSA] with a velocity>0.4 ng/ml per year or PSA >1.5 ng/ml) and no additional treatment. Adverse events in terms of genitourinary and gastrointestinal toxicity were reported. Results: Themean follow-up of the 121 patients was 32.7months and total 11 patients underwent salvage radiotherapy. Six patients received SRT and hormone therapy. Five patients received SRT alone. 6-month progressionfree survival was observed in total 6 patients receiving SRT and hormone therapy achieved. However, biochemical relapse was documented in two patients, 9.47 and 12.20 months after salvage treatment completed, respectively. Among 5 patients receiving SRT alone, two patients encountered treatment failure. There is 1 patient who had histologically proven local relapse. 6-month progression-free survival was observed in the other 2 patients. Salvage radiotherapy was discontinued on 1 patient, who developed grade 4 ileus after 2400 cGy of radiation. There was also 2 patients getting grade 3 gastrointestinal toxicity, bloody stool and anal ulcer with bleeding, respectively. Otherwise, gastrointestinal toxicity was low. All genitourinary toxicity are grade 1e2. Three patients had no genitourinary symptom. Conclusion: In this preliminary study, combined radiotherapy and hormone therapy seemed provided satisfactory oncologic control after for salvage treatment after primary HIFU failure. Though genitourinary and gastrointestinal toxicity were usually low, Grade 3e4 toxicity was still noted. These results warrant further and longer investigation. MP6-2. PSA FLARE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE OR DOCETAXEL Hui-Ying Liu, Yuan-Chi Shen, Cheng-Jen Yu, Po-Hui Chiang. Division of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taiwan Purpose: The aim of this study was to assess PSA flare up phenomenon in the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients with abiraterone or docetaxel and to correlate with clinical outcome. Materials and Methods: We retrospectively evaluated 92 patients with metastatic castrate-resistant prostate cancer (CRPC) either treated with abiraterone or docetaxel at our institution. Baseline serum PSA levels were checked before treatment and followed bymonitoring every 4weeks in the group of abiraterone and every cycle in the groupof docetaxel. The PSAflare phenomenonwas evaluated. Clinical outcomes were evaluated to compare survival between groups of patients according to variations of PSA level. Results: Of 92 patients, 73 patients received docetaxel therapy and 19 patients treated with abiraterone. They were classified into four groups: stabilization (PSA decline <50%), PSA progression, primary responder (PSA decline S 50%), and flare-up phenomenon. Six patients (8.2%) got docetaxel therapy and two patients (10.5%) got abiraterone therapy were identified with PSA flare phenomenon. We compared the overall survival between group of PSA decline> 50% with the flare-up group. There was no statistical difference in survival between two groups. Conclusion: There is a considerable portion of mCRPC patients experience PSA flare under either abiraterone or docetaxel therapy. There was no statistical difference in survival between PSA responder and PSA flare-up phenomenon group. Patients should be informed of this effect to avoid early, and thereby inadequate, discontinuation of treatment. MP6-3. SYSTEMIC REVIEW OF MALIGNANCY AFTER ILEOCYSTOPLASTY Chi-Wen Lo, Shang Jen Chang, Chang-Hsin Hsieh, Shei-Dei Yang. Divisions of Urology, Department of Surgery, Taipei Tzu Chi Hospital, New Taipei,

PSA flare in metastatic castration-resistant prostate cancer patients treated with abiraterone or docetaxel